Tivic Appoints Lisa Wolf as Permanent CFO, Blake Gurfein Steps Down as CSO

Tivic Health has appointed Lisa Wolf as permanent Chief Financial Officer, having served as interim CFO for the last nine months. Blake Gurfein has stepped down as Chief Scientific Officer and will assume a consultant role to support the Vagus Nerve Stimulation program.

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, has announced significant leadership changes following its annual meeting held on June 30, 2025. Shareholders approved key proposals to support the company's strategic transformation, and Lisa Wolf was appointed as the permanent Chief Financial Officer (CFO). Concurrently, Blake Gurfein stepped down as Chief Scientific Officer (CSO) to assume a consultant role.

Lisa Wolf, who has been serving as the interim CFO for the last nine months, has been instrumental in supporting Tivic's financial architecture during its expansion. Her appointment as the permanent CFO reflects her extensive experience and contributions to the company's financial strategy. Wolf will continue to work closely with Jennifer Ernst, the CEO of Tivic Health, as they navigate the company's growth and strategic initiatives.

Blake Gurfein, who served as the CSO for eight years, played a pivotal role in developing and commercializing ClearUP, Tivic's first FDA-approved product. He will now assume a consultant role to support the Vagus Nerve Stimulation (VNS) program, focusing on product and intellectual property development. This change allows Gurfein to leverage his expertise while making way for new leadership within the scientific division.

The shareholder approval of key proposals, including the issuance of equity as a form of payment for Entolimod and Entolasta therapies, underscores Tivic's commitment to expanding its biopharmaceutical markets. These therapies are being developed for uses in acute radiation syndrome, neutropenia, and other oncology and hematology indications. The company has also secured exclusive rights for Entolimod's use in treating neutropenia, a market estimated to reach nearly $21 billion worldwide by 2032.

Tivic Health's strategic transformation is poised to capitalize on the growing demand for innovative immunotherapeutics and bioelectronic therapies. The appointment of Lisa Wolf as CFO and Blake Gurfein's transition to a consultant role reflect the company's dedication to fostering a dynamic and forward-thinking leadership team.

References:
[1] https://www.businesswire.com/news/home/20250708263695/en/Tivic-Shareholders-Approve-Key-Proposals-in-Support-of-Strategic-Transformation-Lisa-Wolf-Appointed-Permanent-CFO
[2] https://www.investing.com/news/stock-market-news/tivic-health-stock-rises-after-shareholders-approve-strategic-proposals-93CH-4126570
[3] https://www.marketscreener.com/quote/stock/TIVIC-HEALTH-SYSTEMS-INC-129226105/news/Tivic-Health-Systems-Inc-Appoints-Lisa-Wolf-as-Permanent-Chief-Financial-Officer-Effective-July-7-50454980/
[4] https://www.marketscreener.com/quote/stock/TIVIC-HEALTH-SYSTEMS-INC-129226105/news/Tivic-Shareholders-Approve-Key-Proposals-in-Support-of-Strategic-Transformation-Lisa-Wolf-Appointed-50457440/